Aggrecan knockdown ATDC5 chondroprogenitor cells have decreased Alcian blue staining and absorbance levels compared to control cells after ITS stimulation. by Juanita K. Hodax (6848540)

A typical GABA-MRS spectrum, where peaks of GABA, NAA, and combined glutamate and glutamine (Glx) are measured. by Hiroyuki Matsuta (13250169)

Lubrication Behavior of Fullerene-Coated Nanoparticles on Rough Surfaces by Guangchao Han (1453198)

Predicted distance (km) needed to achieve a correlation coefficient of at least r =  0.50 using the median-based linear regression models. by Claire Stevens (11127729)

Relationship between the decrease in hunting licences and excess mortality, in each province: Relationship in 2020–2021 (a), in 2021–2022 (b) and between 2021–2022 licences and 202... by Jacopo Cerri (6271958)

The proposed mechanisms for the protective effect of TC-HT against H₂O₂ or Aβ-induced neural injury. by Wei-Ting Chen (167673)

Ivermectin significantly decreases <i>L</i>. <i>loa</i> mf in BALB/c mice. by Rene Bilingwe Ayiseh (6900296)

Image1_The 5HT4R agonist velusetrag efficacy on neuropathic chronic intestinal pseudo-obstruction in PrP-SCA7-92Q transgenic mice.JPEG by Yongqiang Liu (651861)

“…Herein, we report the characterization of the PrP-SCA7-92Q transgenic (Tg) line as a valuable CIPO mouse model and investigated the tolerability and efficacy of the 5-hydroxytryptamine type-4 receptor (5HT4R) agonist velusetrag as a promising pharmacological treatment for CIPO.…”

Image3_The 5HT4R agonist velusetrag efficacy on neuropathic chronic intestinal pseudo-obstruction in PrP-SCA7-92Q transgenic mice.JPEG by Yongqiang Liu (651861)

“…Herein, we report the characterization of the PrP-SCA7-92Q transgenic (Tg) line as a valuable CIPO mouse model and investigated the tolerability and efficacy of the 5-hydroxytryptamine type-4 receptor (5HT4R) agonist velusetrag as a promising pharmacological treatment for CIPO.…”

Image2_The 5HT4R agonist velusetrag efficacy on neuropathic chronic intestinal pseudo-obstruction in PrP-SCA7-92Q transgenic mice.JPEG by Yongqiang Liu (651861)

“…Herein, we report the characterization of the PrP-SCA7-92Q transgenic (Tg) line as a valuable CIPO mouse model and investigated the tolerability and efficacy of the 5-hydroxytryptamine type-4 receptor (5HT4R) agonist velusetrag as a promising pharmacological treatment for CIPO.…”

ROS levels, cell viability, and LDH and Fe²⁺ content in HT22 cells after XMU-MP-1 treatment. by Lu Li (14069)

Simulated effects of increased pCREB combined with decreased pCaMKIIα on bistability. by Yili Zhang (540283)

“…However, decreasing <i>k</i>_{<i>basalp_CaMKII</i>} by ~50% blocked the bistable switch (red). …”

Image_1_Prenatal Protein Malnutrition Leads to Hemispheric Differences in the Extracellular Concentrations of Norepinephrine, Dopamine and Serotonin in the Medial Prefrontal Cortex... by David J. Mokler (4062886)

“…In rats exposed to PPM there was a decrease in extracellular concentrations of NE and DA in the right vmPFC and an increase in the extracellular concentration of 5-HT in the left vmPFC compared to controls (prenatally malnourished: N = 10, well-nourished: N = 20). …”

Kaplan-Meier survival curves for overall survival of MBC by highest tertile of IFN-γ signature vs. the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Study flow diagram. by Christina Gillezeau (5348660)

Subjects:

Kaplan–Meier survival curves for overall survival of NMIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Sample flow diagram. by Christina Gillezeau (5348660)

Subjects:

Kaplan-Meier survival curves for overall survival of MIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Kaplan-Meier survival curves for progression-free survival of MIBC by highest tertile of IFN-γ signature vs the lowest two tertiles. by Christina Gillezeau (5348660)

Subjects:

Characteristics of bladder cancer patients by stage. by Christina Gillezeau (5348660)

Subjects: